|
James T. Slama 419-530-1925 Phone |
|
Institutions/Degrees
| A.B., 1972 | Cornell University |
| Ph.D., 1977 | University of California, Berkeley |
| Research Fellow in Pharmacology, 1977-1979 | Harvard Medical School |
| Research Associate in Chemistry, 1979-1982 | University of Chicago |
Medicinal/pharmaceutical chemistry; organic chemistry. Mechanisms of enzymatic and organic reactions, design of specific mechanism-based enzymye inhibitors, structure and synthesis of natural products of biochemical interest.
Research Interests
The general focus of our research is on glycosidases, glycosyltransferases, nucleosidases, and ADP-ribosyl transferases. Each of these enzyme families defines an important area of research and each offers novel opportunities for new drug development. Glycosidases are important in the digestion of carbohydrates and in the biosynthesis of glycoproteins containing complex carbohydrate chains. Glycosyl transferases utilize nucleoside diphosphate sugars and are responsible for the biosynthesis of complex carbohydrates, glycoproteins, and glycolipids, and in microorganisms for the synthesis of the cell wall. Nucleosidases function in nucleotide and nucleotide salvage pathways targeted by a variety of anticancer, immunosuppressive, and antiprotozoal drugs. Last, ADP-ribosyl transferases catalyze transfer of the ADP-ribose moiety of NAD to a variety of macromolecular acceptors. The functions of ADP-ribosyl transfer reactions are poorly understood, but roles in cell regulation seems likely. Compounds that target ADP-ribosyl transfer reactions could therefore constitute a new class of drugs.

Our experimental approach combines efforts directed toward the design and synthesis of mechanism based enzyme inhibitors with biochemical studies on targeted enzymes, utilizing both conventional and recombinant DNA-based approaches. The goal is to better understand the metabolism and biological function of each enzyme family and at the same time define the specific enzymatic targets relevant to drug development.

As an example, some of our recent work focuses on studies on ADP-ribosyl transfer reactions where oxidized nicotinamide adenine dinucleotide (NAD) serves as an adenosine diphosphate ribose (ADP-ribose) donor. CarbaNAD was the first successful designed inhibitor for this class of enzyme. In carbaNAD a cyclopentane ring replaces the furanose of the nicotinamide ribonucleoside moiety. CarbaNAD is therefore resistant to nicotinamide ribotide cleavage but is recognized as a competitive inhibitor by several ADP-ribosyl transferases.
Adenosine diphosphate (hydroxymethyl)pyrrolidinediol (ADP-HPD) is another example of a successful designed inhibitor. ADP-HPD is a nitrogen-in-the-ring analog of ADP-ribose and a potent inhibitor of poly(ADP-ribose) glycohydrolase. Poly(ADP-ribose) glycohydrolase catalyzes the degradation of ADP-ribose polymers, which are synthesized in the nucleus as a response to DNA damage. ADP-HPD will serve as a useful biochemical probe for deciphering the structure and mechanism of this glycohydrolase. It will also be applied in ongoing studies to elucidate the function of ADP-ribose metabolism following DNA damage. Last, it will serve as a lead compound for the development of inhibitors with improved stability and bioavailability, which may be useful as antitumor drugs.

Representative Publications